MicroRNA-142 在过敏性疾病中的作用及研究进展

先永 宋(承德医学院附属医院耳鼻喉科，中国)
宇丽 张(承德医学院附属医院耳鼻喉科，中国)

摘要

MicroRNA（ miRNA）是短的单链非编码RNA，重要的遗传调节因子，与过敏性、感染性和肿瘤等疾病相关。目前过敏性疾病都具有挑战性，尤其是进展期过敏性疾病的治疗及预后。过敏反应，又称超敏反应，是指机体受到某些抗原刺激，出现生理功能紊乱或组织细胞损伤的异常适应性免疫应答。本综述旨在汇集有关miRNA-142调节过敏性疾病的最新发现，包括变应性鼻炎（ Allergic rhinitis,AR）、过敏性哮喘（ Allergic asthma,AA）和多发性硬化症（ Multiple sclerosis,MS），讨论miR-142和过敏性疾病领域的未来前景，这让miR-142有望作为过敏性疾病潜在标志物，为科学研究、临床精准诊断和新型靶向治疗提供线索和指导。

关键词

miRNA-142；变应性鼻炎；过敏性哮喘；多发性硬化

参考

Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation[J].Science,2004,303(5654):83-86.

Kramer NJ, Wang WL, Reyes EY, et al. Altered lymphopoiesis

and immunodeficiency in miR-142 null mice[J].Blood,2015,

(24):3720-3730.

Lin RJ, Xiao DW, Liao LD, et al. MiR-142-3p as a potential

prognostic biomarker for esophageal squamous cell carcinoma[J].

Surg Oncol,2012,105(2):175-182.

Liu H, Ma G, Xing E, et al. Expression and diagnostic value of

miR-142-5p and miR-155-5p in the serum of children with allergic

rhinitis[J].Int J Pediatr Otorhinolaryngol,2023(165):111425.

Teng ZX, Zhou XC, Xu RT, et al. Tfh Exosomes Derived from

Allergic Rhinitis Promote DC Maturation Through miR-142-5p/

CDK5/STAT3 Pathway[J].Inflamm Res,2022(15):3187-3205.

Wang JY, Dong X, Yu Z,et al. Borneol inhibits CD4 + T cells

proliferation by down-regulating miR-26a and miR-142-3p to

attenuate asthma[J].Int Immunopharmacol,2021(90):107223.

Maes T, Cobos FA, Schleich F, et al. Asthma inflammatory

phenotypes show differential microRNA expression in sputum[J].

Allergy Clin Immunol,2016,137(5):1433-1446.

De Vito F, Balletta S, Caioli S, et al. MiR-142-3p is a Critical

Modulator of TNF-mediated Neuronal Toxicity in Multiple

Sclerosis[J].Curr Neuropharmacol,2023,21(12):2567-2582.

De Vito F, Musella A, Fresegna D, et al. MiR-142-3p regulates

synaptopathy-driven disease progression in multiple sclerosis[J].

Neuropathol Appl Neurobiol,2022,48(2):12765.

Sievers C, Meira M, Hoffmann F, et al. Altered microRNA expression in B lymphocytes in multiple sclerosis: towards abetter understanding of treatment effects[J].Clin Immunol,2012,144(1):70-79.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v6i12.14924